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Summary: An amidolytic assay using the chromogenic Substrate tosyl-glycyl-prolyl-lysine-4-nitranilide acetate
(Chromozym PL®) has been studied for the determination of ̂  -antitrypsin in serum and in cerebrospinal fluid
(CSF). It was found that binding of trypsin to a2-macroglobulin has to be taken into consideration when 0^-
antitrypsin is determined by an amidolytic assay. In serum this accounts for 7.4 ± 3.2% and in CSF 2.8 ± 1.8%
of the total antitrypsin capacity. The reference ränge of ÄJ -antitrypsin in sera was found to be 3T= 60.3 ± 20.8
kIU/1, and in CSF = 186 ± 99 IU/1. Within-run precision showed a C.V. of l.36% in sera, and a C.V. of l .86%
in CSF. There was a good correlation with immunochemical methods: r = 0.946 in 65 sera (p < 0.001) and
r = 0.986 in 55 samples of CSF (p < 0.001).
Bestimmung von oti-Antitrypsin in Serum und Liquor mit einem chromogenen Substrat
Zusammenfassung: Es wurde ein photometrisches Verfahren mit dem chromogenen Substrat Tosyl-glycyl-prolyl-
lysin-4-nitranilidacetat (Chromozym PL®) zur Bestimmung des o^ -Antitrypsingehaltes im Serum und im Liquor
untersucht. Dabei ist bei der Bestimmung des c^-Antitrypsins die Bindung von Trypsin an a2-Makroglobulin zu
berücksichtigen. Im Serum wurde dafür ein Anteil von 7,4 ± 3,2% und im Liquor von 2,8 ± 1,8% an der gesamten
Antitrypsinkapazität ermittelt. Als Referenzbereich von c^ -Antitrypsin wurden folgende Werte gefunden: im Serum
= 60,3 ± 20,8 kIU/1 und im Liquor = 186 ± 99 IU/1. Für die Präzision in der Serie wurde im Serum ein VK von
1,36 und im Liquor von 1,86% erhalten. Weiterhin bestand eine ausgezeichnete Übereinstimmung zu immun-
chemischen Methoden: r = 0,946 in 65 Seren (p < 0,001) sowie r = 0,986 in 55 Liquorproben (p < 0,001).
Introduction
Evaluation of the seruin-CSF barrier gradient of ax -anti-
trypsin has received increasing attention within recent
years (2,3). However, the determination of AI-anti-
trypsin in serum with an amidolytic assay provides
several problems. It is known from the literature that
an increase in the dilution of serum or plasma results
in a greater Inhibition of trypsin activity (4). A dilution
of one hundred times exhibits the largest degree of in-
hibition. Further dilution of rnore than five hundred
times leads to a marked decrease in the Inhibition of
trypsin activity (4). The development of a number of
chromogeiyc Substrates has provided a Substrate for
the determination of dj -antitrypsin according to the
äbove conditions. Mqreover, cerebrospinal fluid (CSF)
should be assayed without ä preparation step prior to
the photometric assay. It is well established that trypsin
also binds to other antiproteases, like c^-macroglobulin.
*) Presented in part at the XL International/IV. European
Congress of Clinical Chemistry, Vienna, Austria, Sept. 1981 (1)
2) STJ: soybean trypsin inhibitor
Inter-a-trypsin-inhibitor e)diibits a lower affinity to
trypsin than other antiproteases and is therefore of
minor importance (5). However, the influence of a2-
macroglobulin on the assay has to beconsidered. The
reaction of the assay can be scheduled äs follows:
l a. Trypsin + &i -antitrypsin -^"- trypsin-^-antitrypsin
complex (inactive)
+ trypsin (free,
active)
l b. Trypsin + a2 -macroglobulin-^· trypsin-a2 macro-
globulin complex
(active) + trypsin
(free, active)
Trypsin (free,active)+STI2)-=^ trypsin-STI complex
(inactive)
2. Chromozym PL® ^-(active) - peptide -H 4.nitro-
aniline
(active trypsin = free trypsin + trypsin-a2-
macroglobulin complex)
It was the purpose of this study to evaluate optimal
conditions for such an amidolytic assay.
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Materials and Methods ^
Samples
65 sera and 55 samples of cerebrospinal fluid, representing ,_,
unselected clinical material which had bcen sent to our labor- ·| 10
atory , wcre investigated. For determination of kinetic para- ^
meters, within-run, and day to day precision a pool serum of e
20 healthy donors and a CSF pool of 20 samples selected at —·
random were taken. All samples were immediately frozen at 5
- 20 °C and analyzed within 4 weeks. α ι -antitrypsin is known
to remain stable within this period (6).
Prior to the photometric assay, sera were diluted 1 + 100
with a solution of 9 g/l of sodium Chloride.
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Reagents and procedures
Protein was measured in sera and in CSF by Standard pro-
cedures (7, 8). Cell count in CSF was estimated from a micro-
scopic count. Immunochemical levels of a\ -antitrypsin were
calculated from immunodiffusion (NOR-Partigen and LC-
Partigen, Behring Institute Marburg, F.R.G.) (9). For the
amidolytic assay, the reagents were commercial preparatipns
of analytical grade, purchased from Boehringer Mannheim,
F.R.G. (Chromozym TH®, Chromozym TRY®, and Chromozym
PL®, trypsin (33 U/mg protein with benzoyl-/)>Z,-arginine-4-
nitroanilide s Substrate), and soybean trypsin Inhibitor (STI)).
The buffer consisted of 0.05 mol/1 of triethanolamine and
0.15 mol/1 of sodium chloride, adjusted to pH 8.0. The
following CSF values were considered normal: protein level
below 500 mg/1, cell count below 3 cells/mm3, no red cells
on microscopic examihation. For the calculation of the
serum/CSF barrier gradient, sera exhibiting c^-antitrypsin levels
below 2 g/l and more than 4 g/l were excluded. "m-values were
calculated from Eadie-Hofstee plots (10,11).
Results
Methodological studies
The chromogenic Substrates Chromozym TH®, Chromo-
zym TRY®, and Chromozym PL® were evaluated for
determination of o^-antitrypsin in serum. The Substrates
Chromozym TH® and Chromozym TRY®, both very
sensitive to trypsin, require a dilution of sera of at least
600 fold; the Substrate Chromozym PL®, however,
required only a dilution of one hundred fold (high levels
of <*!-antitrypsin in serum require a 200 fold dilution)
and corresponded to the conditions mentioned above.
This dilution resulted in a change of absorbance of
ΔΑ/min = 0.4 for the chromogenic Substrate Chiomo-
zym PL®; for the Substrates Chromozym TH® and
TRY®, however, a change of absorbance of ΔΑ/min
= 2.6 was observed.
A linear slope furiction representing the Splitting of the
Substrate Chromozym PL® by trypsin was obtained
over a wide r nge. A change of absorbance of ΔΑ/min
= 0.350 corresponded to a final concentration of 25
U/l trypsin. In further experiments it was revealed that
the Substrate Chromozym PL® is split by the trypsin-
a2-macroglobulin complex, s already described for
other Substrates (12,13).
Kinetics of Inhibition of the amidolytic activity of
trypsin by o^ -antitrypsin were evaluated at 25 °C and
37 °C (fig. 1). It is evident that trypsin reacts slowly
with c*!-antitrypsin: half-rate at 25 °C was determined
to be 142 seconds and at 37 0C to be 59 seconds (fig. 1).
Fig. 1. Variation of the incubation time of trypsin with a pre-
diluted serum at 25 °C (a) and at 37 °C (·) (Standard
conditions). Prolongation of incubation leads to
decrease of free .trypsin.
Stepwise addition of diluted serum leads to a n n-
competitive inhibition of the amidolytic activity of
trypsin (fig. 2). For the Splitting of the chromogenic
Substrate Chrornpzym PL® by trypsin, the Km was
2 Χ l O"5 mol/1, independent of the amount of diluted
serum in the assay.
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Fig. 2. Non-competitive inhibition of the amidolytic activity
of trypsin by stepwise addition of diluted pool serum
(Standard conditions) (·: no addition of diluted
serum, o: addition of pool serum, dil ted l :400,
·: addition of pool serum, diluted 1:200, X: addition
of pool Serum, diluted l:100;i : ainount of α ι -anti-
trypsin in Inhibitory Units).
Tab. 1. Contribution of a2-macroglobulin to the total antl·
trypsin capacity, depending ori the orj-antitrypsin levels
in serum and in CSF.
Level of antitrypsin in serum % of the total antitrypsin
capacity due
globulin
< 2.5 g/l (n = 19)
2.5-4.0 g/l (n =
> 4.0 g/l (n = 18)
Total (n g 65)
28)
13.5 ± 9.2
7.7 ± 2.6
4.2 ±1.8
7.4 ± 3.2
Levels of antitrypsin in CSF % of the total antitrypsin
capacity due to ofc-rnacio-
globulin
< 20 mg/1 (n = 32)
20-50 mg/1 (n = 14)
> 50 mg/1 (n = 9)
Total (n = 55)
3.4 ±1.7
1,8 ± 0.9
2.5 ± 1.9
2.8 ± 1.8
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In simultaneous assays, the contribution by a2-macro-
globulin to the total antitrypsin amount was deter-
mined s previously described (12,13), using the ability
of a2-macroglobulin to form a trypsin-protein com-
plex, which retains its amidolytic activity, also in the
presence of soybean trypsin Inhibitor. These results are
summarized in table 1. It is evident that in the case of
a low α ι -antitrypsin level, a considerable part of trypsin
will be bound to a2-macroglobulin.
All this considered, the photometric assays can be
summarized s follows:
assay a)
0.40 ml of buffer with trypsin (25 U/l)
0.02 ml of sample (serum dilution 1 + 100 or CSF)
6 min incubation
0.05 ml of Chromozym PL® (3.2 X l (T4 mol/1)
increase in absorbance at 405 nm; d = l cm, 37 °C;
assay b)
0.40 ml of buffer with trypsin (25 U/l)
0.02 ml of sample (serum dilution 1 + 100 or CSF)
l min incubation
0.01 ml soybean trypsin inhibitor (5 X 10"̂  mol/1)
0.05 ml of Chromozym PL® (3.2 Χ l O"4 mol/1)
increase in absorbance at 405 nm; d = l cm, 37 PC.
Calculation was performed s follows:
AA/mintrypsin
- AA/minsample(assay a)
— ΔΑ/mina^acjogfcbuKn (assay b)
= ΔΑ/mintrypsin inhibited by *i -antitrypsin
Using a pool serum the assay revealed a good linearity
over a wide r nge (fig. 3). In the case of serum, the
assay should be earried out in the r nge from 400 to
800 IU/13) (sera should be diluted 100 fold or 200
fold, respectively); evaluation of the CSF levels, how-
ever, covers the total r nge.
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Fig. 3. Linearity of the assay, obtained with a pool serum
(Standard conditions; IU: amount of <*i -antitrypsin in
Inhibitory Units).
As the CSF samples were taken without dilution, the
unspecific Splitting of the chromogenic Substrate was
evaluated in the CSF samples: even in the pathological
r nge unspecific Splitting did not exceed 0.5% of total
Splitting.
Reference r nge
With the assay, the normal r nge of c^ -antitrypsin in
sera was found to be 60.3 ± 20.8 kIU/1 (n = 65) (total
protein concentration 72 ± 9.2 g/l). In CSF, the refer-
ence r nge was 186 ± 99 IU/1 (n = 55) (total protein
did not exceed 500 mg/1); no sex differences were
observed.
Within-run precision and detection limit
Within-run precision was χ = 52.3 ± 0.71 kIU/1
(C.V. = l .36%) for pool serum and χ = 326 ± 6 IU/1
(C.V. = 1.86%) for a CSF pool. Detection limit in
CSF was 12 IU/1.
Day to day precision
For serum, day to day precision was found to be
χ = 55.1 ± 1.53 kIU/1 (C.V. = 2.78%) and for CSF
χ = 319 ± 11 IU/1 (C.V. = 3.45%).
Correlation^with immunodiffusion
There was a good correlation with immunodiffusion in
sera s well s in CSF (r = 0.946 for 65 sera (p < 0.001),
and r = 0.986 for 50 samples of CSF (p < 0.001), fig. 4
and 5). Linear regression analysis showed the equation
y = 0.054 χ + 0.05 for sera and y = 0.070 χ - 3.2 for
CSF. 5 samples of CSF had to be excluded because of
their low o^ -antitrypsin levels (not detectable with
immunodiffusion).
Serum-CSF barrier gradient
Using the sera that exhibited an oti -antitrypsin level from
2 to 4 g/l and the CSF samples that were considered
normal, the serum-CSF barrier gradient was calculated.
Using the amidolytic assay, a gradient of 276 was found,
while immunodiffusion gave a value of 269.
l8·0
6.0
4.0
2.0
l
3) l IU = l Inhibitor Unit = the amount of α ι -antitrypsin, which
inhibits l U umol/min) of trypsin (Chromozym PL® s the
Substrate) ·*'·
S 0 20 40 60 80 100 120 140
ce^Antitrypsin (amidolytic assay) [kIU/1]
Fig. 4. Comparison of the amidolytic assay ofaj-antitrypsin
with immunodiffusion in 65 sera at random
(y = 0.054 χ + 0.05, r = 0.946, p < 0.001; IU: amount
of <*i-antitrypsin in Inhibitory Units).
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Fig. 5. Comparison of the amidolytic assay of cq-antitrypsin
with immunodiffusion in 50 CSF samples at random
(y = 0.070 - 3.2, r = 0.986, p < 0.001; IU: amount
of<*i-antitrypsin in Inhibitory Units).
Discussion
It is well known that o^ -antitrypsin can be regarded the
major Inhibitor of trypsin in serum. However, the
amount of trypsin bound to o^-macroglobulin is variable.
Consequently, an exact determination of o^ -antitrypsin
using a functional assay requires exploration of the a2-
macroglobulin level. On the other hand, in CSF the low
levels of a2macroglobulin are negligible.
It is well known that the chromogenic Substrate
Chromozym PL® is also split by other serine pro-
teases like plasmin. As plasmin generally does not
occur äs a free protease in plasina or serum, an un-
specific Splitting of the chromogenic Substrate by
free plasmin can be ruled out.
Our results suggest a serum-CSF barrier gradient of
ca. 270 for oti -antitrypsin, whidi agrees with the
Undings of Felgenhauer (14).
It has already been repörted that c^-antitrypsin reacts
slowly with trypsin (4). In a previous study, we demon-
strated that trypsin reacts rapidly with ai-macroglobiilin
(13). Up to ftow, the understandihg of the physiological
relevance of these pbservatiöns is very pob'r. Takada et
al. (4) assumed that binding of trypsin to o^-macror
globulin may have a protective effect, thus preserving
the efficacy of the proteinase in breaking down physiö-
logically active substances such äs peptide hormones.
Two recent reports have pointed to the diagnostic
relevance of the determination of aA -antitrypsin in CSF.
In patients with intracranial tumours, raised levels could
be observed (3). On the other hand, markedly lowered
levels were repörted in patients suffering from multiple
sclerosis (2). It is interesting that in the case of multiple
sclerosis, serum levels remain unaffected, while the
decrease of the -antitrypsin level in CSF is evident
(2).
These findings suggest that in these cases j -antitrypsin
is involved in the local immune respönse. Data, recently
presented by Arora et al (15), iiidicate that %-anti-
trypsin is an effector of irnmunolbgical stasis, (Ki-änti-
tiypsin was fpund to suppress the in^vitro and in-vivo
immune response: iricreasing amounts of -antitrypsin
resulted in even,greater suppression of immune response
(15).
All these cönsiderations make it apparent that ä deter-
mination of ÄJ -antitrypsin can be used with advantage
in the diagnpsis of various neurological diseases. As
lowered levels of a^ -antitrypsin in CSF cannot be
exactly quantified by immunodiffusion, an amidolytic
assay might be useful.
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